Page last updated: 2024-09-05

sorafenib and Skin Neoplasms

sorafenib has been researched along with Skin Neoplasms in 68 studies

Research

Studies (68)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	22 (32.35)	29.6817
2010's	41 (60.29)	24.3611
2020's	5 (7.35)	2.80

Authors

Authors	Studies
El-Gamal, MI; Jung, MH; Lee, WS; Oh, CH; Sim, T; Yoo, KH	1
Ghosn, M; Ghosn, S; Halabi-Tawil, M; Kaikati, J; Matar, S	1
Franken, MG; Gheorghe, M; Haanen, JBAG; Leeneman, B; Uyl-de Groot, CA; van Baal, PHM	1
Jung, KE; Kim, CD; Kim, KI; Shin, YB; Yoon, TJ	1
Ebrahim, S; Hashemi, S; Moosavi, MA; Motamedi, M; Rahmati, M	1
Colmenero, I; Hernández-Martín, Á; Martos-Cabrera, L; Mateos-Mayo, A; Ramírez-Lluch, M; Torrelo, A	1
Cai, M; Huang, W; Xing, Y; Zhu, L; Zhuo, J	1
Lim, SY; Menzies, AM; Rizos, H	1
Moorthy, A; Srivastava, A	1
Annunziata, CM; Azad, N; Calvo, K; Chen, CC; Choyke, P; Davidson, B; Edelman, DC; Henning, R; Kohn, EC; Meltzer, P; Minasian, L; Steinberg, SM; Venkatesan, A; Wood, BJ; Yu, M	1
Breaker, K; Flaig, IP; Flaig, TW; La Rosa, FG; Naam, M	1
El Tal, AK; Ganger, LK; Mehregan, DA; Remichofsky, CJ	1
Allegra, M; Bahadoran, P; Ballotti, R; Giacchero, D; Hofman, P; Lacour, JP; Le Duff, F; Long-Mira, E; Passeron, T	1
Degen, A; Egberts, F; Garbe, C; Gutzmer, R; Hauschild, A; Kilian, K; Poppe, LM; Trefzer, U; Ugurel, S; Weichenthal, M	1
Allegra, M; Bahadoran, P; Ballotti, R; Bastian, BC; Bollag, G; Botton, T; Burton, EA; Garrido, MC; LeBoit, PE; McCalmont, TH; Nelson, T; Rocchi, S; Sparatta, A; Vemula, SS; Yeh, I	1
Adelmann, CH; Baccarini, M; Busaidy, NL; Ching, G; Chitsazzadeh, V; Ciurea, AM; Curry, JL; Duvic, M; Dwyer, DW; Ehrenreiter, K; Ma, H; Ojeda, SS; Ruggieri, R; Tannir, NM; Tsai, KY; Vin, H	1
D'Andrea, K; Flaherty, KT; Kirkwood, JM; Kluger, HM; Lee, SJ; Letrero, R; Nathanson, KL; Rimm, DL; Schuchter, LM; Wilson, MA; Zhao, F	1
Bernardo, L; Borger, DR; Chen, YB; Durazzo, T; Fathi, AT; Kroshinsky, D; Lin, WM; McAfee, SL; Piris, A; Sadrzadeh, H	1
Albares, MP; Berbegal, L; Blanes, MM; de León, FJ	1
Djokovic, D; Duarte, A; Gigante, J; Harris, AL; Pinho, M; Trindade, A	1
Okano, S	1
Gerber, JM; Grunwald, MR; Induru, R; McDonnell, MH	1
Cohen, PR; Diwan, AH; Evans, HL; Hong, DS; Kurzrock, R; Prieto, VG; Reddy, SB; Tannir, NM; Wright, JJ	1
Chanco Turner, ML; Chevreau, C; Fojo, T; Hornyak, TJ; Kong, HH; Sibaud, V	1
Egberts, F; Hauschild, A; Kahler, KC; Livingstone, E	1
Ardavanis, A; Doufexis, D; Kountourakis, P; Rigatos, G	1
Bar-Eli, M; Melnikova, VO	1
Jorda, E; Lopez, V; Marti, N; Monteagudo, C; Pinazo, I	1
Bennani-Lahlou, M; Escudier, B; Massard, C; Mateus, C; Robert, C; Soria, JC; Spatz, A	1
Poust, J	1
Camp, RL; Flaherty, KT; Jilaveanu, L; Kluger, HM; Lee, SJ; Nathanson, KL; Rimm, DL; Zito, C	1
Arbiser, JL	1
Dubauskas, Z; Hwu, P; Jonasch, E; Kunishige, J; Prieto, VG; Tannir, NM	1
Lee, F; Richmond, A; Smykla, R; Thu, YM; Yang, J; Zaja-Milatovic, S	1
Frieling, T; Heise, J; Wassilew, SW	1
Aractingi, S; Arnault, JP; Escudier, B; Grange, JD; Malka, D; Mateus, C; Poirier-Colame, V; Robert, C; Sibaud, V; Soria, JC; Spatz, A; Tomasic, G; Wechsler, J	1
Haley, H; Hamza, S; Skelton, HG; Smith, KJ	1
Jaworsky, C; Kish, LS; Kwon, EJ	1
Dudek, AZ; Franklin, MJ; Spector, E; Truskinovsky, AM	1
Aziz, SA; Camp, RL; Conrad, PJ; Jilaveanu, LB; Kluger, HM; Rimm, DL; Schmitz, JC; Sznol, M; Zito, CR	1
Cozzio, A; Donghi, D; Dummer, R	1
Hurlstone, A; Wellbrock, C	1
Dobrovic, A; Hamilton, AL; Handolias, D; Kerr, L; McArthur, GA; Moodie, K; Salemi, R; Tan, A	1
Degen, A; Gutzmer, R; Hauschild, A; Kapp, A; Satzger, I; Voelker, B	1
Beck, D; Berger, A; Flaherty, K; Garbe, C; Gogel, J; Kulms, D; Lasithiotakis, K; Maczey, E; Mauthe, M; Meier, F; Niessner, H; Proikas-Cezanne, T; Schadendorf, D; Schaller, M; Schittek, B; Sinnberg, T; Toulany, M; Venturelli, S	1
Nelson, KC; Puri, PK; Raymond, AK; Selim, MA; Tyler, DS	1
Donaldson, MR; Smith, JL; Stetson, CL	1
Amaravadi, RK; Li, LZ; Lum, JJ; Ma, XH; McAfee, QW; Nathanson, KL; Piao, S; Wang, D	1
Adnot-Desanlis, L; Bernard, P; Reguiaï, Z	1
Adams, DR; Lynch, MC; Straub, R	1
Cohen, PR; Stewart, DJ; Williams, VL	1
Boulinguez, S	1
Affolter, A; Ahmad, T; Chao, D; Chevreau, C; Corrie, P; Eisen, T; Gibbens, I; Gore, ME; Harries, M; James, MG; Jouary, T; Lorigan, P; Marais, R; Montegriffo, E; Nathan, PD; Negrier, S; Ottensmeier, C; Prendergast, S; Robert, C; Strauss, UP	1
Bedeir, A; Berger, W; Ghassemi, S; Grasl-Kraupp, B; Grusch, M; Heffeter, P; Heinzle, C; Held, G; Holzmann, K; Marian, B; Metzner, T; Micksche, M; Peter-Vörösmarty, B; Pirker, C; Spiegl-Kreinecker, S	1
Ardlie, K; Chalk, CJ; Dziunycz, P; Garraway, LA; Hofbauer, GF; Jones, R; Kamsukom, N; Kee, D; MacConaill, LE; McArthur, GA; Oberholzer, PA; Palescandolo, E; Piris, A; Robert, C; Roden, C; Schadendorf, D; Sucker, A	1
André, J; Arnault, JP; Boussemart, L; Druillennec, S; Dumaz, N; Eggermont, AM; Escudier, B; Eychène, A; Hollville, E; Kamsu-Kom, N; Lacroix, L; Larcher, M; Malka, D; Mateus, C; Robert, C; Sarasin, A; Soria, JC; Spatz, A; Tomasic, G; Vagner, S; Wechsler, J	1
Ishii, M; Kamo, R; Kobayashi, H; Kumei, A; Tamiya, H; Yanagihara, S	1
Augustine, C; Beasley, GM; Brady, MS; Coleman, AP; Davies, MA; Peterson, BL; Raymond, A; Sanders, G; Selim, MA; Tyler, DS	1
Lucas, LM	1
Anderson, BE; Mackay, D; Svoboda, RM; Welsch, MJ	1
Fujisawa, A; Matsumura, Y; Miyachi, Y; Ono, S; Tanioka, M; Tanizaki, H	1
Axelrod, M; Capaldo, BJ; Gioeli, D; Jensen, K; Mackey, A; Roller, DG; Weber, MJ	1
Ashida, S; Fukuhara, H; Inoue, K; Kamada, M; Karashima, T; Kuroda, N; Shuin, T; Taguchi, T; Tamura, K	1
Hauschild, A	1
Flaherty, KT	1
Allison, RR; Cavalieri, R; Finley, J; Gay, HA; Quan, WD	1
Flaherty, KT; Garbe, C; Kulms, D; Lasithiotakis, KG; Maczey, E; Meier, FE; Schittek, B; Sinnberg, TW	1
Peters, NA; Richel, DJ; Stalpers, LJ; Verhoeff, JJ	1

Reviews

12 review(s) available for sorafenib and Skin Neoplasms

Article	Year
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. European journal of cancer (Oxford, England : 1990), 2019, Volume: 123 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Cancer Vaccines; Carboplatin; Dacarbazine; gp100 Melanoma Antigen; Humans; Hydrazines; Imidazoles; Interleukin-2; Ipilimumab; Lenalidomide; Melanoma; Network Meta-Analysis; Nitrosourea Compounds; Nivolumab; Organophosphorus Compounds; Oximes; Paclitaxel; Piperidines; Progression-Free Survival; Proportional Hazards Models; Pyridones; Pyrimidinones; Skin Neoplasms; Sorafenib; Survival Rate; Temozolomide; Treatment Outcome; Vemurafenib	2019
New insights on the role of autophagy in the pathogenesis and treatment of melanoma. Molecular biology reports, 2020, Volume: 47, Issue:11 Topics: Animals; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 5; Carcinogenesis; Gene Expression; Humans; Melanoma; Skin Neoplasms; Sorafenib	2020
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. Cancer, 2017, 06-01, Volume: 123, Issue:S11 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; CTLA-4 Antigen; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunotherapy; Indoles; Ipilimumab; MAP Kinase Kinase 1; Melanoma; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Signal Transduction; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib	2017
Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2013, Volume: 39, Issue:7 Topics: Adult; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Skin Neoplasms; Sorafenib; Sunitinib	2013
[New molecular target therapy for thyroid neoplasms and malignant melanomas]. Nihon Jibiinkoka Gakkai kaiho, 2015, Volume: 118, Issue:11 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Clinical Trials as Topic; Humans; Indoles; Ipilimumab; Melanoma; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Quinolines; Skin Neoplasms; Sorafenib; Sulfonamides; Thyroid Neoplasms; Vemurafenib	2015
Cutaneous manifestations in leukemia patients. Seminars in oncology, 2016, Volume: 43, Issue:3 Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Cytarabine; Dermatomycoses; Etoposide; Humans; Leukemia; Mastocytosis; Niacinamide; Paraneoplastic Syndromes; Phenylurea Compounds; Skin Diseases, Bacterial; Skin Neoplasms; Sorafenib	2016
Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results. Onkologie, 2008, Volume: 31, Issue:7 Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Evidence-Based Medicine; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyridines; Science; Skin Neoplasms; Sorafenib; Treatment Outcome	2008
BRAF as therapeutic target in melanoma. Biochemical pharmacology, 2010, Sep-01, Volume: 80, Issue:5 Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Signal Transduction; Skin Neoplasms; Sorafenib	2010
Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers? Dermatology (Basel, Switzerland), 2010, Volume: 221, Issue:3 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Female; Humans; Male; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Neoplasms; Sorafenib	2010
Sorafenib-induced premalignant and malignant skin lesions. International journal of dermatology, 2011, Volume: 50, Issue:4 Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Niacinamide; Phenylurea Compounds; Precancerous Conditions; Protein Kinase Inhibitors; Pyridines; Skin Neoplasms; Sorafenib	2011
[Clinical studies with sorafenib (Nexavar) in metastatic melanoma]. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2007, Volume: 5, Issue:4 Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib; Treatment Outcome	2007
Sorafenib: delivering a targeted drug to the right targets. Expert review of anticancer therapy, 2007, Volume: 7, Issue:5 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Humans; Kidney Neoplasms; Liver Neoplasms; Melanoma; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib	2007

Trials

6 trial(s) available for sorafenib and Skin Neoplasms

Article	Year
Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort. Molecular & cellular proteomics : MCP, 2013, Volume: 12, Issue:6 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Pharmacological; Cohort Studies; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Genital Neoplasms, Female; Humans; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Nitric Oxide Synthase Type III; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Predictive Value of Tests; Proto-Oncogene Proteins c-akt; Signal Transduction; Skin Neoplasms; Sorafenib; Vascular Endothelial Growth Factor Receptor-2	2013
Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial). Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2013, Volume: 11, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Causality; Comorbidity; Drug Eruptions; Female; Germany; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Prevalence; Recombinant Proteins; Risk Factors; Skin Neoplasms; Sorafenib; Treatment Outcome	2013
Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Jun-15, Volume: 20, Issue:12 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Double-Blind Method; Female; Follow-Up Studies; Genotype; GTP Phosphohydrolases; Humans; Male; Melanoma; Membrane Proteins; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Survival Rate	2014
Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Feb-01, Volume: 15, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Cell Line, Tumor; Disease-Free Survival; Drug Delivery Systems; Humans; Melanoma; Mitogen-Activated Protein Kinase 3; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib; Treatment Outcome	2009
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. British journal of cancer, 2011, Jul-26, Volume: 105, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib	2011
A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity. Annals of surgical oncology, 2012, Volume: 19, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Extremities; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Melanoma; Melphalan; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Array Analysis; Skin Neoplasms; Sorafenib; Tissue Distribution	2012

Other Studies

50 other study(ies) available for sorafenib and Skin Neoplasms

Article	Year
Design, synthesis, and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines. European journal of medicinal chemistry, 2011, Volume: 46, Issue:8 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Melanoma; Mice; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Skin Neoplasms; Sorafenib; Structure-Activity Relationship	2011
Disfiguring sorafenib associated eruptive squamous cell carcinomas in a patient with acute myeloid leukemia. Annales de dermatologie et de venereologie, 2023, Volume: 150, Issue:1 Topics: Carcinoma, Squamous Cell; Exanthema; Humans; Keratoacanthoma; Leukemia, Myeloid, Acute; Skin Neoplasms; Sorafenib	2023
Sorafenib induces pigmentation via the regulation of β-catenin signalling pathway in melanoma cells. Experimental dermatology, 2022, Volume: 31, Issue:1 Topics: Antineoplastic Agents; beta Catenin; Cell Line, Tumor; Humans; Melanoma; Pigmentation; Signal Transduction; Skin Neoplasms; Sorafenib	2022
Penile and scrotal infundibular cysts in an adolescent treated with sorafenib. Pediatric dermatology, 2021, Volume: 38, Issue:2 Topics: Adolescent; Carcinoma, Squamous Cell; Humans; Male; Niacinamide; Phenylurea Compounds; Skin Neoplasms; Sorafenib	2021
Sorafenib derivatives-functionalized gold nanoparticles confer protection against tumor angiogenesis and proliferation via suppression of EGFR and VEGFR-2. Experimental cell research, 2021, 09-01, Volume: 406, Issue:1 Topics: Animals; Antineoplastic Agents; Capillary Permeability; Cell Movement; Cell Proliferation; Drug Carriers; ErbB Receptors; Gene Expression Regulation, Neoplastic; Gold; HCT116 Cells; Human Umbilical Vein Endothelial Cells; Humans; Lung Neoplasms; Matrix Metalloproteinase 2; MCF-7 Cells; Melanoma, Experimental; Metal Nanoparticles; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Proto-Oncogene Proteins c-myc; Skin Neoplasms; Sorafenib; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Zonula Occludens-1 Protein	2021
Sorafenib induces synergistic effect on inhibition of vemurafenib resistant melanoma growth. Frontiers in bioscience (Scholar edition), 2019, 03-01, Volume: 11, Issue:1 Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indoles; Inhibitory Concentration 50; Melanoma; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib	2019
Multiple squamous cell carcinomas following treatment with sorafenib for renal cell carcinoma. International journal of dermatology, 2013, Volume: 52, Issue:12 Topics: Aged; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Humans; Kidney Neoplasms; Male; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Skin Neoplasms; Sorafenib	2013
Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jul-01, Volume: 31, Issue:19 Topics: Aged; Antineoplastic Agents; Arginine; Back; Cell Survival; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Imidazoles; Indoles; Leucine; Lung Neoplasms; MAP Kinase Signaling System; Melanoma; Niacinamide; Oximes; Phenylurea Compounds; Point Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib	2013
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Pigment cell & melanoma research, 2013, Volume: 26, Issue:6 Topics: Adolescent; Adult; Child, Preschool; Enzyme Activation; Female; Gene Rearrangement; Humans; Indoles; Male; MAP Kinase Signaling System; Melanocytes; Melanoma; Middle Aged; Molecular Targeted Therapy; Nevus, Epithelioid and Spindle Cell; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib; Young Adult	2013
Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK. Molecular cancer therapeutics, 2014, Volume: 13, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; MAP Kinase Kinase 4; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinases; raf Kinases; Skin Neoplasms; Sorafenib	2014
Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, Mar-10, Volume: 34, Issue:8 Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Niacinamide; Phenylurea Compounds; Skin Neoplasms; Sorafenib	2016
Cutaneous metastasis from hepatocellular carcinoma after a percutaneous interventional procedure. Actas dermo-sifiliograficas, 2015, Volume: 106, Issue:5 Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Diathermy; Ethanol; Fatal Outcome; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Needles; Neoplasm Seeding; Niacinamide; Phenylurea Compounds; Radiofrequency Therapy; Sclerosing Solutions; Skin Neoplasms; Sorafenib	2015
Incomplete Dll4/Notch signaling inhibition promotes functional angiogenesis supporting the growth of skin papillomas. BMC cancer, 2015, Aug-28, Volume: 15 Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Calcium-Binding Proteins; Disease Progression; Down-Regulation; Gene Deletion; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Mice; Neovascularization, Pathologic; Niacinamide; Papilloma; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Signal Transduction; Skin Neoplasms; Sorafenib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2	2015
Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Archives of dermatology, 2008, Volume: 144, Issue:6 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Diagnosis, Differential; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinolones; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib	2008
Sorafenib-induced eruptive melanocytic lesions. Archives of dermatology, 2008, Volume: 144, Issue:6 Topics: Administration, Oral; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Diagnosis, Differential; Drug Eruptions; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Nevus, Pigmented; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin; Skin Neoplasms; Sorafenib	2008
A Kaposi's sarcoma complete clinical response after sorafenib administration. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:9 Topics: Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sarcoma, Kaposi; Skin Neoplasms; Sorafenib; Treatment Outcome	2008
Searching for the Achilles' heel of melanoma cells: new treatment modalities. Pigment cell & melanoma research, 2008, Volume: 21, Issue:5 Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Clinical Trials as Topic; Enzyme Inhibitors; Folic Acid Antagonists; Humans; Melanoma; Niacinamide; Organoselenium Compounds; Phenylurea Compounds; Pyridines; Pyrimethamine; Skin Neoplasms; Sorafenib; Treatment Outcome; Urea; Vascular Endothelial Growth Factor Receptor-2	2008
Follicular hyperplasia on the face subsequent to therapy with sorafenib. A new skin side effect. Journal of the European Academy of Dermatology and Venereology : JEADV, 2009, Volume: 23, Issue:8 Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Humans; Hyperplasia; Lung Neoplasms; Male; Melanoma; Niacinamide; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Pyridines; Skin; Skin Diseases; Skin Neoplasms; Sorafenib	2009
[Eruptive nevi associated with sorafenib treatment]. Annales de dermatologie et de venereologie, 2008, Volume: 135, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Humans; Male; Middle Aged; Nevus; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib; Young Adult	2008
Targeting metastatic melanoma. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Dec-15, Volume: 65, Issue:24 Suppl 9 Topics: Antibodies, Monoclonal; Antigens, CD; Antineoplastic Agents; Benzenesulfonates; Cancer Vaccines; Clinical Trials as Topic; CTLA-4 Antigen; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Skin Neoplasms; Sorafenib; Thionucleotides	2008
Unexpected autocrine role of vascular endothelial growth factor in squamous cell carcinoma. The Journal of investigative dermatology, 2009, Volume: 129, Issue:3 Topics: Aneuploidy; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Squamous Cell; Gene Expression Regulation, Neoplastic; Mice; Mice, Transgenic; Models, Biological; Mutation; Niacinamide; Phenotype; Phenylurea Compounds; Pyridines; Signal Transduction; Skin Neoplasms; Sorafenib; Vascular Endothelial Growth Factor A	2009
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clinical genitourinary cancer, 2009, Volume: 7, Issue:1 Topics: Aged; Benzenesulfonates; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Drug Eruptions; Female; Humans; Inflammation; Keratoacanthoma; Keratosis, Actinic; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Neoplasms; Sorafenib	2009
Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy. Molecular cancer therapeutics, 2009, Volume: 8, Issue:3 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Dacarbazine; Drug Delivery Systems; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Niacinamide; Phenylurea Compounds; Pyridines; Quinoxalines; Skin Neoplasms; Sorafenib; Substrate Specificity; Temozolomide; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2009
Multiple colon ulcerations, perforation and death during treatment of malignant melanoma with sorafenib. Deutsche medizinische Wochenschrift (1946), 2009, Volume: 134, Issue:28-29 Topics: Abdomen, Acute; Aged; Antineoplastic Agents; Benzenesulfonates; Colectomy; Colonic Diseases; Diarrhea; Fatal Outcome; Humans; Ileostomy; Intestinal Perforation; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Neoplasms; Sorafenib; Ulcer	2009
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Aug-10, Volume: 27, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Female; Follow-Up Studies; Humans; Keratinocytes; Keratoacanthoma; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin; Skin Neoplasms; Sorafenib; Time Factors	2009
Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2009, Volume: 35, Issue:11 Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Female; Humans; Keratoacanthoma; Male; Middle Aged; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Neoplasms; Sorafenib	2009
The histologic spectrum of epithelial neoplasms induced by sorafenib. Journal of the American Academy of Dermatology, 2009, Volume: 61, Issue:3 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Epithelium; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib	2009
Sorafenib induces partial response in metastatic medullary thyroid carcinoma. Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:1 Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Neuroendocrine; Humans; Immunohistochemistry; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Schistosomiasis; Skin Neoplasms; Soft Tissue Neoplasms; Sorafenib; Thyroid Neoplasms	2010
C-Raf is associated with disease progression and cell proliferation in a subset of melanomas. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Sep-15, Volume: 15, Issue:18 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cohort Studies; Disease Progression; Female; Gene Silencing; Humans; Indoles; Male; Melanoma; Middle Aged; Nevus; Niacinamide; Phenols; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Pyridines; RNA, Small Interfering; Sensitivity and Specificity; Skin Neoplasms; Sorafenib; Young Adult	2009
Complete remission in a patient with multifocal metastatic cutaneous angiosarcoma with a combination of paclitaxel and sorafenib. The British journal of dermatology, 2010, Volume: 162, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Male; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Remission Induction; Skin Neoplasms; Sorafenib; Treatment Outcome	2010
Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. British journal of cancer, 2010, Apr-13, Volume: 102, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Female; Humans; Imatinib Mesylate; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Skin Neoplasms; Sorafenib	2010
The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. The Journal of investigative dermatology, 2011, Volume: 131, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Benzenesulfonates; Cell Line, Tumor; Endoplasmic Reticulum; Farnesyltranstransferase; Humans; Melanoma; Mitogen-Activated Protein Kinase Kinases; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Piperidines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyridines; Signal Transduction; Skin Neoplasms; Sorafenib; TOR Serine-Threonine Kinases; Transcription Factor CHOP	2011
Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb. Archives of dermatology, 2010, Volume: 146, Issue:12 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Drug Administration Routes; Follow-Up Studies; Humans; Leg; Male; Melanoma; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib	2010
Invasive squamous cell carcinoma and sorafenib in a black patient. Archives of dermatology, 2011, Volume: 147, Issue:1 Topics: Antineoplastic Agents; Benzenesulfonates; Black People; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Drug Eruptions; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib	2011
Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, May-15, Volume: 17, Issue:10 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Benzenesulfonates; Cell Count; Clinical Trials, Phase II as Topic; Dacarbazine; Drug Resistance, Neoplasm; Humans; Melanoma; Mice; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Skin Neoplasms; Sorafenib; Survival Analysis; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2011
[Squamous cell carcinoma in a patient receiving sorafenib]. Annales de dermatologie et de venereologie, 2011, Volume: 138, Issue:2 Topics: Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cooperative Behavior; Follow-Up Studies; Humans; Interdisciplinary Communication; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin; Skin Neoplasms; Sorafenib; Vascular Endothelial Growth Factor A	2011
Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib. Journal of drugs in dermatology : JDD, 2011, Volume: 10, Issue:3 Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Humans; Keratoacanthoma; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib	2011
[News on melanoma from the 2010 Dermatology Days in Paris]. Annales de dermatologie et de venereologie, 2011, Volume: 138, Issue:5 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Chemotherapy, Adjuvant; Dacarbazine; Dermatology; Evidence-Based Medicine; Humans; Melanoma; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Radiotherapy, Adjuvant; Skin Neoplasms; Sorafenib; Temozolomide; Treatment Outcome	2011
Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition. The Journal of investigative dermatology, 2011, Volume: 131, Issue:10 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Dacarbazine; Drug Screening Assays, Antitumor; Genes, Dominant; Humans; Indoles; Melanocytes; Melanoma; Niacinamide; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins B-raf; Pyridines; Receptors, Fibroblast Growth Factor; Signal Transduction; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib	2011
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Squamous Cell; Female; Gene Expression Regulation, Neoplastic; Genotype; Humans; Indoles; Male; Mass Spectrometry; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib	2012
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jan-01, Volume: 18, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cells, Cultured; Female; Humans; Keratinocytes; Male; Middle Aged; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Pyridines; raf Kinases; ras Proteins; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Skin; Skin Neoplasms; Sorafenib; Tumor Suppressor Protein p53; Ultraviolet Rays	2012
Partial response of angiosarcoma of the scalp to sorafenib: association with decreased expression of vascular endothelial growth factors and their receptors. Clinical and experimental dermatology, 2012, Volume: 37, Issue:7 Topics: Antineoplastic Agents; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Scalp; Skin Neoplasms; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factors	2012
Painful leg mass. The Journal of family practice, 2012, Volume: 61, Issue:5 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Hospice Care; Humans; Kidney Neoplasms; Leg; Liver Neoplasms; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Pain; Palliative Care; Phenylurea Compounds; Prognosis; Pyridines; Skin Neoplasms; Sorafenib; Tomography, X-Ray Computed	2012
Multiple cutaneous metastatic chordomas from the sacrum. Journal of the American Academy of Dermatology, 2012, Volume: 66, Issue:6 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Chordoma; Female; Humans; Niacinamide; Phenylurea Compounds; Pyridines; Sacrum; Skin Neoplasms; Sorafenib	2012
Angiosarcoma of the scalp successfully treated with a single therapy of sorafenib. Archives of dermatology, 2012, Volume: 148, Issue:6 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Female; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Scalp; Skin Neoplasms; Sorafenib; Treatment Outcome	2012
Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma. Molecular cancer therapeutics, 2012, Volume: 11, Issue:11 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; Diclofenac; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Phospholipases A2, Cytosolic; Signal Transduction; Skin Neoplasms; Small Molecule Libraries; Sorafenib	2012
Expression of angiogenesis-related gene profiles and development of resistance to tyrosine-kinase inhibitor in advanced renal cell carcinoma: characterization of sorafenib-resistant cells derived from a cutaneous metastasis. International journal of urology : official journal of the Japanese Urological Association, 2013, Volume: 20, Issue:9 Topics: Aneuploidy; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Primary Cell Culture; Protein Kinase Inhibitors; Skin Neoplasms; Sorafenib; Transcriptome; Tumor Cells, Cultured	2013
Complete response in a cutaneous facial metastatic nodule from renal cell carcinoma after hypofractionated radiotherapy. Dermatology online journal, 2007, Oct-13, Volume: 13, Issue:4 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Facial Neoplasms; Humans; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Palliative Care; Phenylurea Compounds; Pyridines; Remission Induction; Skin Neoplasms; Sorafenib	2007
Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. The Journal of investigative dermatology, 2008, Volume: 128, Issue:8 Topics: Androstadienes; Apoptosis; Benzenesulfonates; Butadienes; Cell Line, Tumor; Cell Proliferation; Chromones; Down-Regulation; Flavonoids; Humans; Mechanistic Target of Rapamycin Complex 1; Melanoma; Mitogen-Activated Protein Kinase Kinases; Morpholines; Multiprotein Complexes; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Invasiveness; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-bcl-2; Pyridines; Signal Transduction; Sirolimus; Skin Neoplasms; Sorafenib; TOR Serine-Threonine Kinases; Transcription Factors; Wortmannin	2008
Bowel perforation after radiotherapy in a patient receiving sorafenib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, May-10, Volume: 26, Issue:14 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Intestinal Perforation; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Radiation Injuries; Skin Neoplasms; Sorafenib	2008